Results
Message from Serge Weinberg, Chairman of the Board of Directors
Dear shareholders,
2016 was an important year for the implementation of the 2020 roadmap. The first key step in the reorganization of the portfolio was achieved with the completion of the business swap with Boehringer Ingelheim. The exchange of our Animal Health business for their Consumer Healthcare business, positions Sanofi among the top three players in the Consumer Healthcare market worldwide...
Interview with Olivier Brandicourt, CEO
Are you satisfied with your full-year results for 2016?
Overall, our financial performance in 2016 was stronger than we had initially expected at the beginning of 2016...
What are your comments on recent product approvals?
Two months after the approval of Soliqua™ 100/33 in the United States for the treatment of type 2 diabetes, the product was registered in Europe under the brand name Suliqua™...
What about Dupixent®, the other product from your Immunology franchise?
Like Kevzara™, Dupixent® (dupilumab) has been developed in collaboration with Regeneron. We completed the filing of this breakthrough innovation...
Full-Year 2016 Results
Solid financial performance in 2016 supported by cost savings
In 2016, Sanofi’s total sales were up 1.2% and Business EPS was up 4.1% at CER. Exchange rate movements had a negative impact of 1.9 percentage point on sales and 3.4 points on Business EPS.
Sanofi 's solid results were supported by approximately €650M in cost savings delivered in 2016...
News
Soliqua™: treatment in type 2 diabetes
Soliqua™ 100/33 launched in the U.S., Suliqua™ approved in Europe
On January 4, 2017, Sanofi announced that Soliqua™ 100/33 (insulin glargine 100 units/ml and lixisenatide 33 mcg/ml, solution for injection) is now available by prescription in pharmacies in the United States. On January 17, the product was approved in the European Union under the brand name Suliqua™...
Annual General Meeting 2017
Sanofi holds its General Meeting on May 10, 2017 at the Palais des Congrès in Paris.
The main items on the agenda will be:
- the approval of the 2016 financial statements and the payment of a dividend of €2.96 per share;
- the composition of the Board of Directors: reappointment of a director and appointment of new directors...
- Read the article
- More information about the General Meeting 2017
- More information about the 2016 dividend
More news
- Partnership for the production of biological drugs
- KevzaraTM approved in Canada in rheumatoid arthritis
- Stay of permanent injunction for Praluent® granted during appeals process in the U.S.
- Executive Committee: Kathleen Tregoning appointed Executive Vice-President for External Affairs
- Trophées 2016 – Le Revenu: Sanofi wins Silver Award for the best shareholder services
-
rel="noopener noreferrer"
- Read the news
- All Sanofi news
Focus
Sanofi Consumer Healthcare
Committed to people’s well-being in everyday life
Sanofi Consumer Healthcare (CHC) is the newest of our global business units (GBUs), established last year. Throughout 2016, the GBU made considerable progress on one of the strategic priorities of our 2020 roadmap: build a competitive position in Consumer Healthcare globally. A milestone was achieved on January 1st, 2017 with the closing of the transaction between Sanofi and Boehringer Ingelheim (BI) wherein we exchanged Sanofi ’s Animal Health business and BI’s CHC business in most markets...
3 questions to... Alan Main
Executive Vice President, Consumer Healthcare
Sanofi CHC has performed consistently since 2009. What will be happening in 2017?
2017 will be marked by the integration of BI’s CHC business...
What exactly changes for Sanofi CHC with the transaction?
The acquisition of BI’s iconic brands immediately lifts us into leadership positions in strategic OTC categories...
What are your priorities for the future?
We place people at the center of what we do. We don’t treat patients; we empower consumers to take care of their everyday health issues so they can live healthier, fuller lives...
Shareholder information
Subscribe to the electronic version of our publications
In 2017, the Letter to Shareholders will become more digital. As of June, you will be able to read a digital, interactive and easy to use version of the Letter on all your screens: computer, tablet and smartphone.For all those who receive it by postal mail, we would like you to change or confirm your subscription to the Letter by calling us: +33 (0) 800 075 876.
If you don’t wish to subscribe, you can of course continue to read our publications on our website: www.sanofi.com/shareholders
54 rue La Boétie
75008 Paris FRANCE
France +33 800 075 876 • individualshareholders@sanofi.com
United States +1 888 516 3002